[History and pharmacology of trazodone].
Trazodone, a non-tricyclic molecule, represents the first of a new generation of antidepressants. It is currently marketed in a number of European countries, in the United States and in Latin America. The pharmacological and biochemical data, the mechanism of action and the preferential indications of trazodone are presented and compared to those of imipramine and other tricyclics. Unlike imipramine, trazodone inhibits the adrenergic system. The two molecules have anti-nociceptive properties, similar effects on the serotoninergic system and, after repeated administrations, they both reduce the density of beta-receptors. The clinical implications of the alpha-blocking activity of trazodone are reported. Trazodone is preferable to tricyclic anti-depressants in the treatment of depression in elderly subjects in general, and especially when they present closed angle glaucoma, prostatic hypertrophy, tremor or cardiovascular problems due to hyperactivity of the adrenergic system, as well as in organic depressions and in depression secondary to schizophrenia, alcoholism and in patients with Parkinson's disease.
D000700:Analgesics; D000818:Animals; D001921:Brain / Q000378:metabolism; D003866:Depressive Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism; D051381:Rats; D014196:Trazodone / Q000494:pharmacology / Q000627:therapeutic use*
D000700:Analgesics; D018377:Neurotransmitter Agents; D007099:Imipramine; D014196:Trazodone
Historique et pharmacologie de la trazodone.